Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid LeukemiaGiovanni Marconi,Alfonso Piciocchi,Ernesta Audisio,Giorgio Priolo,Cristina Papayannidis,Maurizio Martelli,Francesca Paoloni,Roberto Massimo Lemoli,Monica Bocchia,Francesco Lanza,Albana Lico,Fabio Ciceri,Matteo G. Della Porta,Marco Frigeni,Luisa Giaccone,Germana Beltrami,Erika Borlenghi,Maria Chiara Di Chio,Carmine Selleri,Enrico Crea,Irene Urbino,Chiara Sartor,Clara Minotti,Fabio Guolo,Edoardo La Sala,Jacopo Nanni,Giorgia Simonetti,Maria Teresa Bochicchio,Giuseppe Saglio,Adriano Venditti,Marco Vignetti,Paola Fazi,Giovanni MartinelliBlood(2022)Cited 3|Views23AI Read ScienceMust-Reading TreeExampleGenerate MRT to find the research sequence of this paperChat PaperSummary is being generated by the instructions you defined